Market Launch Planning

September 3, 2026 · What comparable light-therapy companies did before FDA clearance, and what that means for the Lumimed launch.

Production Tracker · Open item checklist

Companies Reviewed

Seven companies, chosen for the closest commercial shape to Lumimed: intranasal or facial light devices sold direct to consumers, plus the enforcement cases that show where the line sits.

• Vielight (Toronto): intranasal and transcranial photobiomodulation headsets sold to consumers, with a separate medical version in an FDA-reviewed trial.
  • Neuro Gamma and the intranasal line: consumer wellness devices, including a nasal applicator, sold under the FDA general-wellness policy.
  • Neuro RX Gamma: the medical version, in a 228-patient pivotal trial for moderate to severe Alzheimer's, not for sale.
• OptoCeutics (Copenhagen): 40 Hz light-and-sound stimulation aimed at cognitive health.
  • EVY LIGHT: sold now as a general-wellness product while the company pursues FDA medical-device approval for Alzheimer's.
• Tivic Health: the closest commercial comparator for a nasal congestion device.
  • ClearUP Sinus Relief: an external microcurrent device that went through a full De Novo review (DEN200006) before it was sold for congestion relief.
• Omnilux: the benchmark for how a cleared consumer light device presents itself.
  • Omnilux Contour Face: FDA-cleared for facial wrinkles, sold with a narrow indication, a defined regimen and contraindications.
• Kineon: a red-light joint device that shows the tension between marketing copy and regulatory status.
  • MOVE+: sold with pain, healing and inflammation language while its own help center said the device was "not officially classified as a photobiomodulation device" to comply with FDA guidelines; the current model now holds a 510(k) for knee pain relief.
• Marci Beauty and Vevazz: the two FDA warning-letter cases for light-therapy devices sold beyond, or without, clearance.
• Willow Curve: the FTC case for a light-therapy device sold on unsupported pain claims and a false "FDA approved" claim.

Marketing Prior FDA Clearance - Market Examples

Selling While FDA Review Is in Process

We also looked for examples of companies who had similar products and sold them while FDA work was still open, or without doing any FDA work at all. A few fall into that category, and each one differs from Lumimed in how much of a medical claim it makes.

• Vielight sells a consumer version while the medical version stays in trials. The Neuro Gamma is on the shelf as a wellness device while the Neuro RX Gamma, the same technology under a different name, runs the pivotal Alzheimer's trial that started in 2019.
  • The company's own position is that a claim for Alzheimer's has to be earned through the regulatory process, so the trial is what buys the claim.
  • The consumer pages sell mental wellbeing, immunity and recovery, and never name a disease.
  • Source: Vielight pivotal trial announcement.
• OptoCeutics sells the same device it is putting through the FDA. EVY LIGHT is on sale now as a general wellness product while the clinical trials and the FDA pathway continue on that same product.
  • The product page says plainly that the device "is still considered experimental, is not a medical device" and is available under the wellness policy.
  • The Alzheimer's connection appears only as what customers report, never as a company claim.
  • Source: EVY product page.
• Kineon sold on claims its own help center said it could not make. The MOVE+ storefront ran pain, healing and inflammation language while the help center said the device was not classified as a photobiomodulation device in order to comply with FDA guidelines.
  • The current model now holds a 510(k) for knee pain relief, so the clearance came after the selling.
  • This is the version of the strategy we would not copy.
  • Sources: Kineon product page, Kineon help center.

Conclusion: The two companies doing this cleanly sell a product that has nothing to do with a disease, and they keep the medical claim on a separate track with a separate name. Neither one is trying to sell a device for a condition it has a pending submission for, which is exactly what Lumimed would be doing. Their products also sit on the head or in front of the eyes rather than inside the nose, so the wellness policy is available to them in a way it may not be to us.

Enforcement Examples

• Marci Beauty (FDA warning letter, February 2021): several light-therapy products marketed without clearance or approval; FDA cited disease and structure/function claims, asked the company to stop distributing for those uses, and rejected reliance on another manufacturer's clearance because the devices and indications differed. Letter.
• Vevazz (FDA warning letter, December 2019): the company held clearances for limited LED uses, then promoted neuropathy, inflammation, scars and wrinkles; FDA treated the expanded uses as new, unapproved intended uses and noted that a symptom-relief clearance does not authorize treating the underlying disease. Letter.
• Willow Curve (FTC, June 2020): unsupported claims that a light-therapy device treated chronic pain and inflammation, plus a false "FDA approved" claim; $22 million judgment, mostly suspended after two $200,000 payments, with standing limits on future health claims. FTC release.

The Challenges for Lumimed

Three things stand between Lumimed and a wellness-style launch, and each one is enough on its own.

• The device goes inside the nose, which the current guidance treats as invasive. The wellness route the two in-process companies use is only open to products that are low risk and non-invasive.
  • The January 2026 FDA general wellness guidance defines invasive as penetrating skin or mucous membranes.
  • An applicator that delivers light inside the nose meets that definition on its face.
  • Vielight and OptoCeutics both sit outside the body, which is part of why the route works for them.
• FDA reads the whole record, not the label. A clean website would not by itself make this a wellness product.
  • Lumimed's record includes a clinical history and a pre-submission that both say allergic rhinitis.
  • Intended use can be drawn from product design, development history and what people say about it, not only from the packaging.
  • That record is already with the FDA, so it is not something a new brand voice can sit on top of.
• Every health claim needs our own data behind it. The FTC requires product-specific evidence, so softening the language does not lower the evidence bar.
  • Even light congestion or breathing language would need Lumimed's own results, not the wider red-light literature.
  • Evidence for a different device, wavelength or ingredient does not carry over.
  • The Willow Curve case below is what this looks like when it goes wrong.

Launch Without Clearance: Pros and Cons

What if FDA clearance is not given?

While we're in alignment regarding the importance and value of FDA clearance, approval is not certain. Looking at comparable market cases, here there would still be several viable options for Lumimed:

• 1. A claim-free device sold on comfort and routine. Strip every medical claim and sell the hardware for what it physically is, a nasal light device used as part of a daily routine, the way Vielight sells its intranasal line.
  • No allergy, rhinitis, congestion or symptom language anywhere on the site, the box, the manual or the ads.
  • The mucous-membrane question still has to be answered first, so this is the option that most needs a regulatory read before anything ships.
  • Lowest revenue per customer of the three, because the reason to buy has to come from the brand rather than the benefit.
• 2. Physician-supplied through the practice and a referral network. Supply the device through clinicians who already treat these patients, rather than through a consumer storefront.
  • Dr. B's own practice and the Superior Associates referral network are a built-in first channel.
  • A physician-supplied device carries a different risk profile than a direct-to-consumer sale, and the conversation happens in the exam room rather than in an ad.
  • Smaller volume, but it produces real use data and clinician feedback that feed the next submission.
• 3. License or partner the technology. Take the device, the tooling, the testing package and the regulatory file to a company that already sells in this category and has a cleared product line.
  • Revenue comes from a licensing fee or a partnership rather than from unit sales, so no consumer sale happens before clearance.
  • The FDA work done so far is an asset in that conversation, not a sunk cost.
  • ClearUP's owner Tivic and the larger consumer light-therapy brands are the natural first calls.

Conclusions and Next Steps

FDA clearance is the plan and it is worth the push, because it is the only route that lets Lumimed say what the device actually does. Nothing in this review found a company selling an intranasal device for a condition it had a pending submission on, so the near-term work is finishing the clearance path while the launch gets built behind it.

• Build and test the 30 pilot units. They stay internal, and they tell us what the housings and the assembly actually look like before the larger runs.
• Ask MRC for general guidance on what, if anything, can be said or sold before clearance.
• Keep the launch build going. Brand, packaging, storefront, fulfillment and pricing can all be finished now without publishing, seeding or selling, so clearance day is a switch rather than a project.